LIVE: FDA Vaccines Advisory Committee Meets on Moderna's mRNA Influenza Vaccine MFLUSIVA

The FDA Vaccines and Related Biological Products Advisory Committee holds a meeting at 8:30 a.m. ET on June 18 to discuss and make recommendations on the safety and effectiveness of MFLUSIVA (Influenza Vaccine, mRNA), manufactured by Moderna TX Inc., with a requested indication in Biologics License Application STN 125869/0 for the prevention of influenza disease caused by influenza virus subtypes A and B represented in the vaccine, in persons 50 years of age and older.
Video Summary
AI GeneratedThe VRBPAC meeting reviewed Moderna's mFluZiva (mRNA-1010), a trivalent mRNA influenza vaccine for adults 50+. The committee evaluated clinical trial data showing superior efficacy and immunogenicity compared to standard-dose vaccines. Despite higher transient reactogenicity, the committee unanimously voted that the benefits outweigh the risks for adults 50–64 and 65+.
